目的 探讨培美曲塞联合奥沙利铂作为二线化疗方案对复发性卵巢癌患者的疗效及临床安全性。方法 将2011年5月至2012年4月天津医科大学附属肿瘤医院收治的49例复发性卵巢癌患者随机分为观察组和对照组，观察组23例患者第1天iv培美曲塞500 mg/m2，iv奥沙利铂135 mg/m2，3周为一疗程；对照组26例患者第1、8天iv吉西他滨1 000 mg/m2，第2天iv奥沙利铂135 mg/m2，3周为一疗程。所有患者均接受4个以上疗程，每2个疗程评价疗效及不良反应。结果 两组有效率差异无显著性（P＞0.05），但观察组的不良反应明显减轻（P＜0.05），患者可以耐受。结论 培美曲塞联合奥沙利铂作为二线化疗方案治疗复发性卵巢癌不良反应较轻，患者能够耐受，可以提高患者的生存质量，值得临床进一步研究。

Objective To study the clinical efficacy and safety of pemetrexed combined with oxaliplatin as second-line chemotherapy to treat patients with recurrence ovarian cancer (ROC). Methods A total of 49 patients with ROC, who received the treatment from May 2011 to April 2012 in Tianjin Medical University Cancer Institute and Hospital, were definitely divided into observation group (n=23) and control group (n=26). The patients in the observation group were iv administered with pemetrexed (500 mg/m2) and oxaliplatin (135 mg/m2) on day 1, three weeks as a course; The patients in the control group were iv administered with gemeitabine (1 000 mg/m2) on day 1 and day 8, and with oxaliplatin (135 mg/m2) on day 2, three weeks as a course. All patients received four or more treatment courses, the clinical efficacy and adverse events were compared between the two groups after every two courses of treatment. Results There was no significant difference (P > 0.05) between the two groups, but the adverse reactions in the observation group were reduced significantly (P < 0.05), and the patients could tolerate. Conclusion Pemetrexed combined with oxaliplatin, as second-line chemotherapy, is an effective treatment program with less adverse reactions and the patients could tolerate. At the same time, this program could improve the life quality of patients, which is worthy of further study in clinic.